Abstract:3550 Background: Cell-free DNA (cfDNA) methylation, fragmentation patterns, chromosome instability, and chromatin accessiblity have been previously shown to be valid plasma biomarkers for non-invasive cancer detection. However, conventional whole-genome bisulfite sequencing (WGBS) is unable to simultaneously profile all these biomarkers due to bisulfite-induced DNA damages. Here we developed a machine learning approach to comprehensively integrate multiple types of cancer genomic markers from enzyme-conversion-based low-pass whole-methylome sequencing (WMS) of plasma cfDNA to non-invasively detect colorectal adenocarcinoma. Methods: Plasma cfDNA sampels from 215 colorectal adenocarcinoma patients and 568 healthy individuals were collected and were split into the discovery and independent testing cohort. The discovery cohort includes 150 cancer patients and 398 healthy individuals and the independent testing cohort includes 65 cancer patients and 170 healthy individuals. Whole methylome sequencing (WMS) libraries were generated from enzymatically converted cfDNA and were subsequently paired-end sequenced at ̃2X coverage. The genome-wide methylation density, fragmentation fingerprints, chromosome instability, and chromatin accessibility were extracted from the WMS data and individually modelled via machine learning methods such as SVM, LR, GBDT, random forest. The final predictive model is an ensemble model integrating all uni-modal models. All models were trained and fitted on the discovery cohort. Results: Data of different modalities provide complementary information in separating the cancer patients from the healthy individuals. Unsupervised clustering of the individuals showed clear separation between cancer patients and healthy individuals. The final predictive model achieved AUC =0.982 in the discovery cohort and AUC =0.9664 in the independent testing cohort. Under a specificity of 94.71% (CI: 90% - 98.82%), sensitivity was 78.46% (CI: 60% - 92.31%) in the independent testing cohort. Separating the cancer patients into different stages, we found that the detection power is usuaul lower for early-stage cancer patients. Conclusions: These results demonstrate the first proof of principle on the feasibility of integrating multiple genomic cancer markers to non-invasively detect colorectal adenocarcinoma from WMS plasma cell-free DNA. A large prospective cohort study is planned to further validate its clinical performance.

Marker for early intestinal cancer screening and adenoma diagnosis and applications thereof

392P Integrating Fragmentomic Features for Non-Invasive Early Detection of Colorectal Advanced Adenoma and Adenocarcinoma

Circulating Bacterial DNA As a Tool Towards Noninvasive Biomarkers for Colorectal Adenocarcinoma and Adenoma.

A fecal-based test for the detection of advanced adenoma and colorectal cancer: a case-control and screening cohort study

Development of fecal microbial diagnostic marker sets of colorectal cancer using natural language processing method

A New Biomarker of Fecal Bacteria for Non-Invasive Diagnosis of Colorectal Cancer

Identification of Microbial Markers Across Populations in Early Detection of Colorectal Cancer

A novel faecal Lachnoclostridium marker for the non-invasive diagnosis of colorectal adenoma and cancer

Superficial modification based 5hmC (5-hydroxymethylcytosine) polymolecular marker and CRC (colorectal cancer) early diagnosis model

A 5-Hydroxymethylcytosine-based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: the METHOD-2 Study

Fecal Bacteria as Non-Invasive Biomarkers for Colorectal Adenocarcinoma

Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers

Supplementary Figure S10 from A 5-Hydroxymethylcytosine-Based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: The METHOD-2 Study

Multi-dimensional fragmentomic assay for ultrasensitive early detection of colorectal advanced adenoma and adenocarcinoma

Early detection of colorectal adenocarcinoma by decoding epigenetic and DNA fragmentation fingerprints of plasma cell-free DNA.

Clinical Application of Marker Based on DNA Methylation in Gastrointestinal Tumor

A novel cell‐free DNA methylation‐based model improves the early detection of colorectal cancer

Sensitive detection of colorectal cancer in peripheral blood by a novel methylation assay

Circulating Bacterial DNA As a Tool Towards Non-Invasive Biomarkers for Colorectal Cancer and Adenoma

DNA methylation detection technology and plasma-based methylation biomarkers in screening of gastrointestinal carcinoma

Cell-free DNA methylation profiles enable early detection of colorectal and gastric cancer